Dhanuka Agritech Limited has informed the Exchange about Investor Presentation
DHANUKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dhanuka Agritech reported strong FY25 results, crossing the Rs 2,000 crore revenue milestone. Q4 FY25 revenue grew 20% YoY to Rs 442.02 crore, with EBITDA up 37% to Rs 109.75 crore and PAT up 27.9% to Rs 75.50 crore. Full-year FY25 revenue stood at Rs 2,035.15 crore (+15.7%), EBITDA at Rs 416.61 crore (+27.2%), and PAT at Rs 296.96 crore (+24.2%). EBITDA margin expanded to 20.47% in FY25 from 18.62% a year ago. The company acquired international rights for two fungicide molecules (Iprovalicarb and Triadimenol) from Bayer AG, expanding its presence to over 20 countries. Management guided for higher double-digit revenue growth going forward and recommended a 100% dividend (Rs 2 per share).
Strong quarterly and annual results with margin expansion, a global acquisition, and a robust product pipeline (8 new products planned over next 2 years) are positive for shareholders. The flat EBITDA guidance for FY26 alongside higher double-digit revenue growth may signal some margin pressure ahead, warranting monitoring.